SEC filing record
Primary Source · SEC.gov

Opus Genetics, Inc.

2024 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2024-11-07Last filing 2024-11-07

Raised

$26M

Investors

11

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Opus Genetics, Inc. is a Delaware corporation that filed a Form D with the SEC on November 7, 2024 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. Opus Genetics, Inc. reported $25,778,641 sold from 11 investors of a $25,778,641 total offering as of the Form D filed November 7, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 8 Davis Drive, Suite 220, Durham, NC 27713.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001228627
Entity NameOpus Genetics, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address8 Davis Drive, Suite 220, Durham, NC 27713
Phone(984) 884-6030
Former NamesOcuphire Pharma, Inc. (until October 22, 2024); REXAHN PHARMACEUTICALS, INC. (until November 9, 2020); CORPORATE ROAD SHOW DOT COM INC (until April 29, 2005); FERRARO FRANK (until April 29, 2003)
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateOctober 22, 2024
Filing DateNovember 7, 2024
Accession Number0001140361-24-045485
Total Offering Amount$25,778,641
Total Amount Sold$25,778,641
Amount Remaining$0
Total Investors11
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$0
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)MI
Amendment Count2 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

1

latest Nov 7, 2024

Critical / warning

0 / 0

1 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

2

closed

Latest event New filer · Nov 7, 2024

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Fund family Part of the Opus Genetics family: 2 vehicles across 0 generations · full family and the filing behind each link in the terminal

Investor

  • The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
  • 1 filing event with values and deltas, latest 2024-11-07, and alerts on the next one
  • 2 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2024-11-07: 7 related persons added and 2 removed against the filing of 2020-11-20; 14 now listed. The names are in the Terminal feed.

Dr. George Magrath

Director, Executive Officer · Farmington Hills, MI

Dr. Benjamin Yerxa

Director, Executive Officer · Farmington Hills, MI

Nirav Jhaveri

Executive Officer · Farmington Hills, MI

Ash Jayagopal

Executive Officer · Farmington Hills, MI

Cam Gallagher

Director · Farmington Hills, MI

Sean Ainsworth

Director · Farmington Hills, MI

Susan Benton

Director · Farmington Hills, MI

James Manuso

Director · Farmington Hills, MI

Richard Rodgers

Director · Farmington Hills, MI

Dr. Jean Bennett

Director · Farmington Hills, MI

Dr. Adrienne Graves

Director · Farmington Hills, MI

Bernhard Hoffmann

Executive Officer · Farmington Hills, MI

Amy Rabourn

Executive Officer · Farmington Hills, MI

Joseph Schachle

Executive Officer · Farmington Hills, MI

Questions About Opus Genetics, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Opus Genetics, Inc.?

Opus Genetics, Inc. is a Delaware corporation that filed a Form D with the SEC on November 7, 2024 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.

Is Opus Genetics, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Opus Genetics, Inc. filed a Form D with the SEC on November 7, 2024 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $25,778,641 sold to 11 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Opus Genetics, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Opus Genetics, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Opus Genetics, Inc. raised?

Opus Genetics, Inc. reported $25,778,641 sold from 11 investors of a $25,778,641 total offering as of the Form D filed November 7, 2024.

Who can invest in Opus Genetics, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Opus Genetics, Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Opus Genetics, Inc. and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Opus Genetics, Inc.?

The Form D lists 14 related persons: Dr. George Magrath, director, executive officer; Dr. Benjamin Yerxa, director, executive officer; Nirav Jhaveri, executive officer; Ash Jayagopal, executive officer; Cam Gallagher, director; Sean Ainsworth, director; Susan Benton, director; James Manuso, director, and 6 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Opus Genetics, Inc. located?

The issuer's address on its SEC filings is 8 Davis Drive, Suite 220, Durham, NC 27713. Its phone number of record is (984) 884-6030. It is organized under the laws of Delaware.

How long is the Opus Genetics, Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

What is Opus Genetics, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.